QTREX Quantum Ltd designs and manufactures cryogenic interconnect systems used in quantum computing systems... Show more
QTREX Quantum Ltd. occupies a deliberately narrow position within the quantum computing value chain. Rather than building qubits or full systems, the company develops high-density, thermally optimized interconnect solutions that carry control and readout signals from room-temperature electronics down to the millikelvin environment inside a dilution refrigerator (the device that cools quantum processors to near absolute zero). As quantum systems scale toward larger qubit counts, conventional cryogenic cabling becomes a bottleneck — imposing constraints on thermal load, mechanical congestion, microwave performance, and manufacturing consistency. QTREX's monolithic interconnect architecture is designed to replace manually assembled discrete cabling and support higher channel density and reliability.
The company's AME (Additively Manufactured Electronics) platform underpins this effort while also serving as a standalone commercial business across aerospace, defense, missile, and space applications. This dual-revenue structure differentiates QTREX from pure quantum startups and provides a nearer-term source of engineering revenue. On the competitive front, the company faces established global interconnect conglomerates expanding into cryogenic technologies alongside specialized engineering firms. Its ability to convert early technical validation into repeatable, scalable manufacturing contracts will define medium-term market positioning.
The most consequential near-term catalyst is the conversion of technical validation into contracted revenue. Management has stated that it expects to announce agreements with additional companies in the current quarter, and the pace and caliber of these announcements will shape investor sentiment around the stock forecast. Any expansion beyond a single flagship customer would meaningfully reduce concentration risk.
Capital allocation decisions represent a second catalyst. The May 2026 $10 million private placement with a fundamental institutional investor strengthened the balance sheet, but future financings, their structure, and the associated dilution will be closely watched. Separately, the company's stated intention to monetize its medical portfolio — including the FDA-cleared INSPIRA ART100 life-support system and the HYLA blood-monitoring platform — offers a potential non-dilutive capital infusion if a strategic transaction is completed.
Because QTEX remains a lightly covered micro-cap, formal analyst ratings and price targets are sparse. Investor attention is instead driven by company-disclosed milestones, technology partnerships, and sector-wide sentiment toward quantum computing. Any initiation of institutional research coverage or upward revision in third-party assessments of the quantum infrastructure market could serve as a positive catalyst, while delays in commercial agreements or manufacturing scale-up could weigh on sentiment.
QTREX's trajectory is tightly linked to the broader quantum computing investment cycle, which is heavily influenced by government funding and venture capital allocation. The United States remains the dominant market for quantum infrastructure, and federal programs supporting quantum research create a structural tailwind for hardware-adjacent suppliers like QTREX. However, the sector remains sensitive to interest rates and risk appetite: higher-for-longer rate environments typically pressure speculative, pre-profit technology valuations and can constrain the venture funding that flows to QTREX's potential customers.
Geopolitical dynamics also cut both ways. Heightened competition in advanced technology, particularly between the U.S. and China, has increased defense and aerospace demand for AME-based electronics manufacturing — a near-term positive for the company's commercial AME business. At the same time, QTREX's Israeli headquarters exposes it to regional security and operational risks. Technology adoption trends, including the pace at which superconducting quantum systems progress toward fault tolerance, will ultimately determine the size of the addressable market for cryogenic interconnect solutions.
Investors tracking developing momentum in QTEX and the broader quantum computing complex can turn to Tickeron's Trend Prediction Engine, an AI-powered forecasting tool designed to help traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the coming week or month. The engine is built to help users spot emerging trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. It includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. As quantum infrastructure names like QTEX experience pronounced volatility around commercial milestones, this kind of signal-driven tool can help investors contextualize price action.
Looking toward 2026 and beyond, QTREX's long-term investment case rests on a simple thesis: quantum computing cannot scale without solving its physical connectivity and thermal management constraints, and the company is positioned directly at that intersection. The key themes to monitor include the pace of customer diversification, the transition from engineering-services revenue toward production-scale manufacturing contracts, and the company's ability to defend its technological differentiation as larger interconnect conglomerates enter the cryogenic space.
Margin sustainability and cost structure will depend heavily on the maturation of the AME platform, where proprietary software, consumable materials, and customer-funded development programs offer higher-margin recurring potential. Competitive threats are real but manageable in the near term, given the highly technical and specialized nature of cryogenic interconnect. Regulatory developments — particularly U.S. export controls on advanced and quantum technologies — could either accelerate domestic sourcing demand for QTREX's solutions or introduce compliance complexity. Capital allocation priorities, including the possible monetization of the medical business and future equity financings, will remain central to how consensus expectations evolve as coverage develops.
Because QTEX trades at a low market capitalization with minimal sell-side coverage, investors should treat any third-party price targets or forecasts with caution and view the company's own disclosed milestones as the primary forward-looking signals.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that QTEX and SSYS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that QTEX and SSYS's prices will move in lockstep.
| Ticker / NAME | Correlation To QTEX | 1D Price Change % | ||
|---|---|---|---|---|
| QTEX | 100% | +10.65% | ||
| SSYS - QTEX | 30% Poorly correlated | -0.87% | ||
| MBAI - QTEX | 29% Poorly correlated | +6.64% | ||
| AGMH - QTEX | 27% Poorly correlated | -12.67% | ||
| UMAC - QTEX | 26% Poorly correlated | -2.62% | ||
| CRSR - QTEX | 26% Poorly correlated | +4.13% | ||
More | ||||
| Ticker / NAME | Correlation To QTEX | 1D Price Change % |
|---|---|---|
| QTEX | 100% | +10.65% |
| Medical Specialties category (43 stocks) | 19% Poorly correlated | +0.34% |
| Medical Specialties category (43 stocks) | 19% Poorly correlated | +0.34% |
| Computer Processing Hardware category (39 stocks) | 13% Poorly correlated | -0.78% |
| Medical/Nursing Services category (139 stocks) | 6% Poorly correlated | +0.94% |
| Health Services category (240 stocks) | 6% Poorly correlated | +0.89% |
Industry ComputerProcessingHardware
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QTEX broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for QTEX entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on QTEX as a result. In 72 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for QTEX just turned positive on October 02, 2026. Looking at past instances where QTEX's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.
QTEX moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for QTEX crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
The 50-day moving average for QTEX moved above the 200-day moving average on October 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +12.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTEX advanced for three days, in 145 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.297) is normal, around the industry mean (7.321). P/E Ratio (0.000) is within average values for comparable stocks, (51.117). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (23.994). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (84.034) is also within normal values, averaging (51.774).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. QTEX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTEX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.